Overview

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Status:
Terminated

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

In this study we plan to study the combination of ZD6474, a dual inhibitor of EGFR and VEGFR-2 with anastrozole in the neoadjuvant setting for patients with Stage I-III breast cancer. The aim is to overcome mechanisms of resistance and simultaneously block multiple critical signaling pathways known to stimulate breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Collaborator:

AstraZeneca

Treatments:

Anastrozole
Hormones